Infectious complications are frequent events in patients undergoing high-dose cytotoxic chemotherapy with subsequent autologous peripheral blood stem cell transplantation (PBSCT). To evaluate whether a single subcutaneous injection of pegfilgrastim (6 mg) is as safe and effective as daily filgrastim (5 lg/kg/day), 60 consecutive autologous stem cell transplantations performed for various haematological malignancies have been analysed. In total, 24 patients undergoing 30 consecutive PBSCT received a single subcutaneous injection of 6 mg pegfilgrastim on day 5 after transplantation and were compared retrospectively with 30 patients receiving 5 lg/kg/day of filgrastim starting from day 7 post transplantation. The mean duration of grade 4 neutropenia in the pegfilgrastim and filgrastim groups was 8.3 and 9.5 days, respectively (P ¼ 0.047). The results of the two groups were not significantly different for incidence of febrile neutropenia and toxicity profile. However, duration of febrile neutropenia (1.6 vs 3.0 days) and total days of fever (1.73 vs 4.1) were different (P ¼ 0.017 and 0.003, respectively), favouring the pegfilgrastim arm. Consequently, a higher incidence of transplants with documented infectious complications associated with the filgrastim group could be observed (56 vs 26%) (P ¼ 0.02). A single injection of pegfilgrastim administered at day 5 post transplant shows comparable safety and efficacy profiles to daily injections of filgrastim. Bone Marrow Transplantation (2005) 35, 889-893.
pheral blood stem cell transplantation; PBSCT The use of high-dose chemotherapy (HDC) followed by autologous haematopoietic stem cell transplantation is an important treatment modality for patients with haematological malignancies that markedly improved the patients' outcome. [1] [2] [3] [4] [5] Haematologic toxicity associated with neutropenic complications is a major limiting toxicity of HDC. The duration of grade 4 neutropenia (ANCo0.5 Â 10 9 /l) and neutrophil function deficiencies in the early post transplant period are correlated with the development of severe infectious complications, which have a major impact on overall morbidity and mortality. 6 Recombinant human granulocyte colony-stimulating factor (R-metHuG-CSF, filgrastim) reduces the risk of neutropenia and its complications by stimulating the production of neutrophil precursors and enhancing the function of mature neutrophils. 7 The administration of filgrastim in patients undergoing autologous transplantation reduced the duration of neutropenia and febrile neutropenia. [8] [9] [10] Filgrastim requires daily subcutaneous administration, since it has a plasma half-life of 3-4 h due to renal and neutrophil-mediated clearance. 11, 12 Polyethylene glycol (PEG)-modification of filgrastim, pegfilgrastim, decreases renal clearance and increases plasma half-life. 11 Thus, only a single injection is required to achieve the same effect as multiple daily injections of filgrastim in patients receiving conventional chemotherapy. The potential benefit of a single injection includes a better patient compliance and increased convenience for both patients and healthcare professionals. In this study, we aimed to evaluate the efficacy and safety of a single fixed 6 mg dose of pegfilgrastim compared to daily administration of filgrastim in patients with haematological malignancies receiving HDC and autologous peripheral blood stem cell transplantation (PBSCT).
Patients and methods

Patient selection
We studied 60 consecutive autologous PBSCTs of 54 pretreated patients with haematological malignancies at the Medical University Graz, Austria from August 2002 to June 2004. During this period, supportive care, type of central venous catheter or empirical antibiotic regimens were not changed. Eligibility for PBSCT included to have an Eastern Cooperative Oncology Group performance status p2, normal cardiac, pulmonary, hepatic and renal function prior to transplantation. Patients were excluded if they had an active infection or had used antimicrobials within 72 h before chemotherapy administration. All individuals gave written informed consent and the protocol was approved by the hospital ethics committee.
Conditioning and transplantation
PBSCT was performed on day 0 with unmanipulated peripheral blood stem cells that were harvested using cyclophosphamide (CY) and G-CSF before the start of the study. Preparative regimen for patients with Hodgkin's disease consisted of CY 1.5 g/m 2 once daily i.v. on days -6 to -3 (total dose 6 g/m 
Study drugs
Patients of the filgrastim (r-metHuG-CSF) group received daily subcutaneous injections of 5 mg/kg/day starting at day þ 7 after transplantation until an ANC 410 Â 10 9 /l. Patients treated with pegfilgrastim (peg-r-metHuG-CSF) received a single 6 mg subcutaneous injection on day þ 5 after transplantation.
Efficacy and safety measurements
The primary end point of the study was duration of grade 4 neutropenia (ANCo0.5 Â 10 9 /l), which was defined as the number of days to achieve an absolute neutrophil count higher than 0.5 Â 10 9 /l (first of at least 3 consecutive days). Secondary end points were incidence of febrile neutropenia (defined as ANC o0.5 Â 10 9 /l and temperature X38.21C), duration of febrile neutropenia, duration of fever and incidence of documented infections (clinically or microbiologically documented infection with/without bacteraemia; definitions according to AGIHO/DGHO guidelines). 13, 14 The safety end point of the study was the incidence of adverse events related to study medication.
Statistical analysis
Differences between the experimental groups were tested by Fisher's exact test and the Mann-Whitney U test. A twosided P-value of o0.05 was considered to indicate statistical significance. No adjustment for multiple testing was performed. Table 1 summarises the baseline characteristics of the patients. 24 patients undergoing 30 consecutive PBSCT (six patients had two consecutive PBSCT) receiving pegfilgrastim and 30 patients receiving filgrastim starting from day 7 post transplantation were compared retrospectively. Patients seemed generally well matched with respect to demographic and physical characteristics except baseline ANC and haemoglobin counts, which were in favour of the pegfilgrastim group. Nevertheless, no significant difference between both study arms regarding the first time point of developing grade 4 neutropenia (day post transplantation reaching ANC o0.5 Â 10 9 /l) could be observed. The mean number of CD34 þ cells infused was not different between the groups.
Results
Patient characteristics
Study drug administration
Patients treated with pefilgrastim received a single dose of 6 mg on day þ 5 after transplantation. The median number of subcutaneous injections administered to patients treated with filgrastim (5 mg/kg/day) was 7.
Efficacy
Duration of grade 4 neutropenia. The day to reach ANC o0.5 Â 10 9 /l was similar in both groups ( Table 1 ). The mean time to reach ANC 40.5 Â 10 9 /l was 8.3 days in the pegfilgrastim group compared to 9.5 days in patients treated with filgrastim (P ¼ 0.047). The range was 5-14 days, respectively. Postnadir ANC recovery to 2.0 Â 10 9 /l was achieved by all patients of both groups after a mean of 9.3 and 11 days, respectively (P ¼ 0.04) ( Table 2) .
Febrile neutropenia and duration of febrile neutropenia. Febrile neutropenia was defined as an oral or oral-equivalent temperature of X38.2C concurrent with an ANC less than 0.5 Â 10 9 /l. The cumulative incidence of febrile neutropenia demonstrated no difference between the experimental groups. However, there was a difference regarding the mean number of febrile days during grade 4 neutropenia ( ¼ duration of FN) with 1.6 days in the pegfilgrastim and 3.0 days in the filgrastim group (P ¼ 0.017). In addition, the mean number of total days of fever (1.73 vs 4.1) were also in favour for the pegfilgrastim arm (P ¼ 0.003) ( Table 2 , Figure 1 ).
Documented infections and microbiological surveillance
Documented infections according to AGIHO/DGHO criteria 13,14 occurred in 26.6% (8/30) transplantations in the pegfilgrastim group vs 56.6% (17/30) receiving filgrastim (P ¼ 0.02). Mainly catheter related infections were more commonly seen in the filgrastim arm accounting for the described difference between the two groups. Further, microbiological surveillance data revealed more positive blood cultures in the filgrastim arm (24 of 18 vs 11 of 10 transplantations) with coagulase negative staphylococci being the most prominent pathogen in both groups ( Table 2) . As opposed to positive blood culture tests documented infections by coagulase negative staphylococci were only considered by two positive blood cultures. None of the patients developed documented fungal infections.
i.v. antibiotics and duration of hospitalisation
The mean duration of intravenous administration of antibiotics was 10.5 days (range 0-22) in the pegfilgrastim and 11.4 days (range 4-23) in the filgrastim arm (NS, P ¼ 0.59). Duration of hospitalisation from day 0 (day of transplantation) to discharge was 15.1 days (9-25) for pegfilgrastim and 16.3 days (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) for the filgrastim group (NS, P ¼ 0.125).
Safety
Most adverse events (AE) were attributable to complications arising from myelo-suppressive chemotherapy or the primary disease. The only occurring AE considered to be cytokine related was mild to moderate bone pain. The overall incidence of bone pain was 20% (6/30) in pegfilgrastim patients and 23% (7/30) in filgrastim patients. In general, bone pain required no medication or was controlled with non-narcotic analgesia ( Table 2 ).
Discussion
Patients with haematological malignancies undergoing HDC and subsequent autologous PBSCT experience a prolonged episode of neutropenia associated with high rates of neutropenic-related morbidity and occasional mortality. Most randomised trials using daily subcutaneous injections of G/M-CSF have shown to significantly shorten duration of neutropenia and hospitalisation 9,10,15,16 and possibly reducing costs. 16, 17 The optimal timing of G-CSF administration is still under investigation. Two randomised studies demonstrated no significant differences in efficacy between early or delayed G-CSF administration (d1 vs d7 18 and d0 vs d3 vs d5 19 ), but both reported cost savings with the delayed treatment. A PEG-conjugated filgrastim, pegfilgrastim, was recently synthesised and displayed a decreased plasma clearance with a resultant increase in half-life, thus making it almost entirely dependent on neutrophil receptor-mediated clearance. 20 This decreased plasma clearance potentially can translate into enhanced clinical efficacy and would be more convenient for patients and health care providers through its once per cycle administration. Clinical trials to test the pharmacokinetics, safety, and efficacy of a single dose pegfilgrastim compared to filgrastim in patients with non-small-cell lung cancer, breast cancer and lymphoma receiving conventional chemotherapy revealed a similar safety and efficacy profile. [20] [21] [22] [23] [24] One trial reported significantly less episodes of febrile neutropenia across all chemotherapy cycles for the pegfilgrastim arm. 21 The present study reveals that a single injection of pegfilgrastim was at least equivalent to a mean of seven daily injections of filgrastim in all efficacy and safety end points evaluated. In accordance with the study of BenceBruckler, 18 our control arm received filgrastim at day 7. Due to the prolonged pharmacokinetic profile it seemed reasonable to initiate pegfilgrastim administration at day 5 assuming an average duration of grade 4 neutropenia of B8 days.
Although we are aware of the limitations of a nonrandomised study, the presented data are in keeping with current published literature comparing conventional filgrastim with pegfilgrastim. The largest trial comprised 310 stage II to IV breast cancer patients, who were randomly assigned to receive 5 mg/kg daily of filgrastim (n ¼ 156) or a single 100 mg/kg dose of pegfilgrastim (n ¼ 154) after chemotherapy. 21 The percentage of patients with febrile neutropenia was 18% in the filgrastim group and 9% in the pegfilgrastim arm (P ¼ 0.29). In our study, we were not able to demonstrate a significant difference in the incidence of febrile neutropenia. However, the duration of febrile neutropenia as well as the entire number of febrile days was profoundly reduced in the pegfilgrastim group (1.4 and 2.3 days, respectively), suggesting a potential therapeutical advantage over standard filgrastim. These results are further substantiated by the observation of a notable decrease of the mean duration of grade 4 neutropenia by 1.2 days in the pegfilgrastim group. The acceleration of neutrophil recovery may also account for the lower incidence of clinically or microbiologically documented infections including positive blood cultures in patients receiving pegfilgrastim.
The prolonged pharmacokinetic profile of pegfilgrastim has raised the concern that this novel agent might have a higher toxicity compared to filgrastim. The most commonly reported toxicities related to G-CSF were bone pain. In accordance with previous studies [21] [22] [23] [24] [25] of patients treated with conventional chemotherapy, bone pain was comparable in both arms, indicating similar overall toxicity profiles.
Together with the convenience of a single dosing and the reductions in the duration of neutropenia, duration of febrile neutropenia and occurrence of documented infections, this study provides further evidence that pegfilgrastim might have potential advantages over standard filgrastim. A fixed-dose pegfilgrastim should facilitate the management of aplasia following autologous stem cell transplantation and may offer significant benefits for patients and health care providers. Consequently, it may serve as an attractive alternative to a repetitive single G-CSF administration modus, particularly in thrombopenic patients experiencing a prolonged neutropenic episode. However, prospective randomised studies are warranted to corroborate these results.
